Lung Cancer Clinical Trial

Hypofractionated Radiotherapy for Lung Cancer

Summary

The purpose of this trial is to pilot reducing the duration of radiation treatment for lung cancer patients from 6 to 5 weeks using tomotherapy. Specific patient doses will be based on tumor volume being treated. Modeling has shown that increased biologically effective dose (BED) to tumors can be achieved by shortening the radiation delivery schedule and increasing the dose per fraction. This requires decreasing the total dose to hold lung toxicity constant at each dose per fraction level. This is a major paradigm shift in the treatment in this disease and is projected to result in significant improvements in patient outcome as well as a substantial cost savings.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Thoracic neoplasm requiring at lest 60 Gy conventional radiotherapy

Exclusion Criteria:

Prior bleomycin or gemcitabine chemotherapy
Prior thoracic radiotherapy

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

79

Study ID:

NCT00214123

Recruitment Status:

Completed

Sponsor:

University of Wisconsin, Madison

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of Wisconsin Hospital and Clinics
Madison Wisconsin, 53792, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

79

Study ID:

NCT00214123

Recruitment Status:

Completed

Sponsor:


University of Wisconsin, Madison

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider